Compare Summit Therapeutics Inc (SMMT) vs Western Digital Corp (WDC) Price & Performance

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.

Western Digital (WDC) trades at $394.13, down 2.73% amid concerns about increased competition from Toshiba's planned HDD production expansion. The stock shows strong fundamentals with three consecutive earnings beats and robust profitability metrics including 71.97% net margin and 131.02% ROE. Technical indicators are bearish with the price testing key support at $387, while analyst consensus remains strongly bullish with a $647.58 price target representing 64% upside potential.

Despite near-term competitive pressures, WDC's dominant market position in AI storage and improving financial performance support long-term growth prospects. Key risks include pricing pressure from increased industry capacity and execution challenges in maintaining cost-per-terabyte reductions. The current valuation at 14.61 P/E appears attractive relative to growth expectations.